Population Health Research Institute

ACTIVE A (Completed)
Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events

< back

Content currently under construction. 

The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular events such as stroke and heart attack during approximately three years of follow-up in patients with atrial fibrillation associated with at least one major risk factor of vascular event such as elderly, blood pressure increase, history of stroke or transient ischemic attack or left ventricular dysfunction etc. The study will also accept patients with atrial fibrillation and unwilling to take oral anticoagulant therapy.

Study Design:  Randomized, Efficacy Study. Double Blind, Placebo Control, Factorial Assignment.

Intervention: Clopidogrel and Aspirin vs. Aspirin alone.

Length of Study:  2.5 years

# of Patients:  7554

Patient Populations: Atrial Fibrillation



Currently unavailable.

Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Currently unavailable




Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca